Page 59 - அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜி News Today : Breaking News, Live Updates & Top Stories | Vimarsana
GT Biopharma : Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patie
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Allogene Therapeutics Receives IND Clearance from the U S Food and Drug Administration for ALLO-715 in Combination with Nirogacestat in Relapsed/Refractory Multiple Myeloma – IT Business Net
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Author Bio
Dr. Orelli is a Senior Biotech Specialist. He has written about biotech, pharmaceutical, and medical device companies for The Motley Fool since 2007.
Follow @BiologyFool
In this video from
Motley Fool Live recorded on Dec. 14, Bureau Chief of Healthcare and Cannabis Corinne Cardina and Fool.com contributor Brian Orelli discussed the boost in
Fate Therapeutics (NASDAQ:FATE) stock price after the biotech presented data on its natural killer (NK) cell therapy.
The company didn t have much data at the American Society of Hematology (ASH) annual meeting. With the investment community focused on blood cancer drugs, Fate took the opportunity to release data for FT516, one of its NK-based treatments, before the conference.
Motley Fool Live, recorded on Dec. 14, Brian talks about why
bluebird bio (NASDAQ:BLUE) is a well-rounded company in the space as it develops treatments for both traditional blood diseases and blood cancer. He also pitches
IGM Biosciences (NASDAQ:IGMS), an up-and-coming drugmaker developing bispecific antibodies to treat blood cancers.
Corinne Cardina: So what would you say are the most intriguing stocks in the hematology space today?
Brian Orelli: I think if you want to invest specifically for hematology, bluebird bio, ticker there is BLUE, is definitely the leader here, because it s working in both blood diseases, sickle cell disease, and beta-thalassemia, and then as well it s in the CAR-T cancer space with Bristol Myers it has a partnership with
Summary
Meet Lymphoma Service Chief Gilles Salles, who recently joined MSK after a long career in France.
Gilles Salles recently joined Memorial Sloan Kettering as Chief of the Lymphoma Service within the Division of Hematologic Malignancies. Dr. Salles came to MSK after a long career at Claude Bernard University in Lyon, France.
In an interview conducted in early December just before the annual American Society of Hematology (ASH) meeting, where he presented updates from several studies he’s conducted, Dr. Salles spoke about his decision to join MSK, his research, and his plans for the Lymphoma Service.
Why did you decide to come to MSK?
vimarsana © 2020. All Rights Reserved.